Larimar Therapeutics, Inc. (LRMR)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.35+3.52%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Larimar Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	2.49M
EPS	—	-0.378
Annual ending 2026-12-31
Revenue	—	2.32M
EPS	—	-1.371
Annual ending 2027-12-31
Revenue	—	41.12M
EPS	—	-1.17

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Sufficient cash and capital to fund operations through FY27	A supporting condition in Larimar Therapeutics, Inc.'s published investment case. The stated target is Maintain cash > $100 million through FY27.	Intact	cash falls below $50 million before FY27	Cash and cash equivalents: $92.687M FY2026-Q2; GAAP. Published target: Maintain cash > $100 million through FY27. Target period is not explicitly aligned with this observation. Source date unavailable92,687,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduction in net loss per share	A primary condition in Larimar Therapeutics, Inc.'s published investment case. The stated target is EPS loss improves from -$1.61 in FY26 to less negative in FY27.	Intact	EPS loss worsens or remains flat beyond FY27	Diluted EPS: $-0.30 per share FY2026-Q2; GAAP. Published target: EPS loss improves from -$1.61 in FY26 to less negative in FY27. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026-0.3 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Larimar achieves ~$200 million revenue in FY26	A primary condition in Larimar Therapeutics, Inc.'s published investment case. The stated target is ~$200 million.	Intact	revenue falls below $150 million in FY26	Revenue: $0 FY2026-Q2; GAAP. Published target: ~$200 million. Target period is not explicitly aligned with this observation. Source published Aug 4, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.17

$-1.22 → $-1.17 · observed estimates

FY2027 revenue$0.04B

$0.06B → $0.04B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.22	$57,069,647	6 / 8
2026-07-25	$-1.22	$57,069,647	6 / 8
2026-07-26	$-1.22	$57,069,647	6 / 8
2026-07-27	$-1.22	$57,069,647	6 / 8
2026-07-28	$-1.22	$57,069,647	6 / 8
2026-07-29	$-1.22	$57,069,647	6 / 8
2026-07-30	$-1.18	$57,064,670	7 / 10
2026-07-31	$-1.18	$57,064,670	7 / 10
2026-08-01	$-1.22	$57,069,647	6 / 8
2026-08-02	$-1.18	$57,064,670	7 / 10
2026-08-03	$-1.18	$57,064,670	7 / 10
2026-08-04	$-1.18	$57,064,670	7 / 10
2026-08-05	$-1.18	$57,064,670	7 / 10
2026-08-06	$-1.22	$57,069,647	6 / 8
2026-08-07	$-1.22	$42,192,834	6 / 6
2026-08-08	$-1.13	$52,858,530	6 / 7
2026-08-09	$-1.13	$52,858,530	6 / 7
2026-08-10	$-1.13	$52,858,530	6 / 7
2026-08-12	$-1.06	$41,682,340	8 / 11
2026-08-13	$-1.22	$42,192,834	6 / 6
2026-08-14	$-1.22	$42,192,834	6 / 6
2026-08-15	$-1.22	$42,192,834	7 / 7
2026-08-16	$-1.22	$42,192,834	7 / 7
2026-08-17	$-1.22	$42,192,834	7 / 7
2026-08-18	$-1.22	$42,192,834	7 / 7
2026-08-19	$-1.22	$42,192,834	7 / 7
2026-08-20	$-1.22	$41,704,652	7 / 8
2026-08-21	$-1.22	$41,704,652	7 / 8
2026-08-22	$-1.22	$41,704,652	7 / 8
2026-08-23	$-1.22	$41,704,652	7 / 8
2026-08-24	$-1.22	$41,704,652	7 / 8
2026-08-25	$-1.22	$41,704,652	7 / 8
2026-08-26	$-1.22	$41,704,652	7 / 8
2026-08-27	$-1.22	$41,704,652	7 / 8
2026-08-28	$-1.22	$41,704,652	7 / 8
2026-08-29	$-1.22	$41,704,652	7 / 8
2026-08-30	$-1.22	$41,704,652	7 / 8
2026-08-31	$-1.22	$41,704,652	7 / 8
2026-09-01	$-1.22	$41,704,652	7 / 8
2026-09-02	$-1.22	$41,704,652	7 / 8
2026-09-03	$-1.22	$41,704,652	7 / 8
2026-09-04	$-1.22	$41,704,652	7 / 8
2026-09-05	$-1.22	$41,704,652	7 / 8
2026-09-06	$-1.22	$41,704,652	7 / 8
2026-09-07	$-1.22	$41,704,652	7 / 8
2026-09-08	$-1.22	$41,704,652	7 / 8
2026-09-09	$-1.22	$41,704,652	7 / 8
2026-09-10	$-1.22	$41,704,652	7 / 8
2026-09-11	$-1.22	$41,704,652	7 / 8
2026-09-12	$-1.22	$41,704,652	7 / 8
2026-09-13	$-1.22	$41,704,652	7 / 8
2026-09-14	$-1.22	$41,704,652	7 / 8
2026-09-15	$-1.18	$41,741,016	7 / 8
2026-09-16	$-1.18	$41,741,016	7 / 8
2026-09-17	$-1.18	$41,741,016	7 / 8
2026-09-18	$-1.18	$41,741,016	7 / 8
2026-09-19	$-1.18	$41,741,016	7 / 8
2026-09-20	$-1.18	$41,741,016	7 / 8
2026-09-21	$-1.18	$41,741,016	7 / 8
2026-09-22	$-1.18	$41,741,016	7 / 8
2026-09-23	$-1.18	$41,741,016	7 / 8
2026-09-24	$-1.18	$41,741,016	7 / 8
2026-09-25	$-1.18	$41,741,016	7 / 8
2026-09-26	$-1.18	$41,741,016	7 / 8
2026-09-27	$-1.18	$41,741,016	7 / 8
2026-09-28	$-1.18	$41,741,016	7 / 8
2026-09-29	$-1.18	$41,741,016	7 / 8
2026-09-30	$-1.18	$41,741,016	7 / 8
2026-10-01	$-1.18	$41,741,016	7 / 8
2026-10-02	$-1.18	$41,741,043	7 / 8
2026-10-03	$-1.18	$41,741,043	7 / 8
2026-10-04	$-1.18	$41,741,043	7 / 8
2026-10-05	$-1.18	$41,741,043	7 / 8
2026-10-06	$-1.18	$41,741,043	7 / 8
2026-10-07	$-1.18	$41,741,043	7 / 8
2026-10-08	$-1.18	$41,741,043	7 / 8
2026-10-09	$-1.18	$41,741,043	7 / 8
2026-10-10	$-1.18	$41,741,043	7 / 8
2026-10-11	$-1.17	$41,121,847	7 / 8
2026-10-12	$-1.17	$41,121,847	7 / 8
2026-10-13	$-1.17	$41,121,847	7 / 8
2026-10-14	$-1.17	$41,121,847	7 / 8
2026-10-15	$-1.17	$41,121,847	7 / 8
2026-10-16	$-1.17	$41,121,847	7 / 8
2026-10-17	$-1.17	$41,121,847	7 / 8
2026-10-18	$-1.17	$41,121,847	7 / 8
2026-10-19	$-1.17	$41,121,847	7 / 8
2026-10-20	$-1.17	$41,121,847	7 / 8
2026-10-21	$-1.17	$41,121,847	7 / 8
2026-10-22	$-1.17	$41,121,847	7 / 8
2026-10-23	$-1.17	$41,121,847	7 / 8
2026-10-24	$-1.17	$41,121,847	7 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	12	0	0
2026-06-01	10	0	0
2026-07-01	11	0	0
2026-08-01	11	0	0
2026-09-01	11	0	0
2026-10-01	11	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Sufficient cash and capital to fund operations through FY27Cash and cash equivalents: $92.687M
Reduction in net loss per shareDiluted EPS: $-0.30 per share
Larimar achieves ~$200 million revenue in FY26Revenue: $0

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-66.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Larimar Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative biotech investment, not an established earnings compounder: LRMR is loss-making and carries high risk. The thesis is intact, with management progressing toward a 2027 launch, but confidence in the evidence snapshot is low.

What's priced into Larimar Therapeutics, Inc.

The snapshot provides no valuation or expectations data, so whether LRMR is cheap or expensive versus peers and what the market already assumes cannot be assessed. The company’s losses and reliance on future regulatory and commercial progress are clear, but the evidence does not show how much of that is reflected in valuation.

What the fundamentals likely do

Near term, results may remain difficult to read: recent earnings beats are positive signals, while the company remains loss-making and the industry has a high rate of misses. Management initiated a rolling submission for accelerated approval in June 2026 and reported study data showing sustained skin FXN levels with directional clinical improvements; completing the submission in the second half of 2026 remains a key execution step. Management continues to target a U.S. launch in the first half of 2027, contingent on approval.

What Larimar Therapeutics, Inc. hinges on

The multi-year view hinges on completing the regulatory submission, obtaining approval, and preparing for the planned launch. A guidance cut or a weaker jobs trend could add near-term pressure, while continued strength among healthcare bellwethers could support the sector backdrop. The evidence does not establish how those sector signals translate to LRMR’s business.